Clinical observation of bifidobacterium triple viable capsule for non-alcoholic steatohepatitis

Objective To evaluate the efficacy and safety of bifidobacterium triple viable capsule in treatment of non-alcoholic steatohepatitis(NASH). Methods Forty-six NASH patients were randomized into a treatment group and a control group. The patients in the control group only received compound glycyrrhizin, 3 pills each time, 3 times daily for 12 weeks and patients in treatment group received bifidobacterium triple viable capsules, 840 mg each time, twice daily for 12 weeks, in addition to the administration of com-pound glycyrrhizin. Clinical symptoms, blood biochemistry indicators, liver and kidney function and serum endotoxin level were observed before and after treatment. Results After therapy, the clinical symptoms of the treatment group were ameliorated more efficiently than those of the control group(P 0.05). Compared with pre-therapy, the levels of ALT, AST and GGT of the two groups post-therapy decreased significantly(P0.05), but the differences were not significant between the two groups. Compared with pre-therapy, the serum endotoxin level of the two groups decreased significantly(P0.05), and the variation of the serum endotoxin level between pre-therapy and post-therapy in the treatment group was significantly greater than that in the control group(P0.05). Conclusions Bifidobacterium triple viable capsule is effective in relieving the clinical symptoms and decreasing the serum endotoxin level in NASH patients. No adverse reaction are found during therapy.